Determination of Gatifloxacin in Human Urine by Liquid Chromatography-Tandem Mass Spectrometry

Authors

  • N. Rajendraprasad PG Department of Chemistry, J.S.S. College, Ooty Road, Mysore, Karnataka, India
  • U.R. Anil Kumar Department of Studies in Chemistry, University of Mysore, Manasagangothri, Mysore, Karnataka, India
  • K. Basavaiah Department of Studies in Chemistry, University of Mysore, Manasagangothri, Mysore, Karnataka, India

DOI:

https://doi.org/10.37591/(rrjops).v6i1.918

Abstract

 

Gatifloxacin (GTF) is an antibiotic of the fourth-generation fluoroquinolone family that inhibits the bacterial enzymes DNA gyrase and topoisomerase IV. A reliable, sensitive and selective isocratic reversed phase liquid chromatographic-tandem mass spectrometric (LC-MS-MS) method was developed to determine gatifloxacin (GTF) in human urine. GTF, in urine after solid-phase extraction with SPE cartridge, was analyzed on a C18 column (Symmetric 3.5 µm; 75×4.6 mm i.d) interfaced with a triple quadrupole tandem mass spectrometer. Positive electrospray ionization was employed as the ionization source. The mobile phase consisted of 5 mM ammonium formate (pH 2.9):acetonitrile (20:80, v/v). A linear relationship was obtained over a concentration range of 10–1000 ng mL-1 GTF with the lower limit of quantitation value of 10 ng mL-1. The intra-day and inter-day relative standard deviation across three validation runs over the entire concentration range was <11.1%. The accuracy determined at three different concentrations of GTF (25.0, 500.0 and 850.0 ng mL-1) was within 1%.

 

Keywords: Gatifloxacin, quantification, liquid chromatography-tandem mass spectrometry

 

Downloads

Published

2021-01-12

Issue

Vol. 6 No. 1 (2015)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.